Linked Life Data

18307840

Source:http://linkedlifedata.com/resource/pubmed/id/18307840

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-2-29
pubmed:abstractText
Intranasal corticosteroids (INCSs) provide safe and effective treatment of allergic rhinitis (AR). Currently available INCSs differ in terms of the components included in each formulation that may influence efficacy, tolerability, and patient preference for treatment. Patient preference for a specific INCS is largely attributable to the sensory attributes that are dependent on characteristics of the formulation. Preservatives and additives can irritate and dry the mucosal membranes, or they can confer an unpleasant odor or taste to an INCS formulation. Spray volume also may affect patients' sensory perceptions of INCS formulations. Relative osmotic pressure or tonicity may affect nasal absorption and retention of an INCS and potentially affect clinical efficacy. A hypotonic suspension is a new formulation option for INCSs that may improve sensory attributes and has the potential to improve patient satisfaction and treatment outcomes in patients with AR. Optimization of INCS formulations may improve efficacy and tolerability and influence patient preference for treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1539-6304
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
28 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S18-24
pubmed:meshHeading
pubmed:articleTitle
Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis.
pubmed:affiliation
Altana Pharma US, 220 Park Avenue, Florham Park, NJ 07932, USA. mark.wingertzahn@altanapharma-us.com
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't